Efficacy and safety of prophylactic anticoagulation in patients with primary nephrotic syndrome: a systematic review and meta‐analysis

Abstract

AbstractBackground and AimsNephrotic syndrome (NS) is associated with an increased incidence of venous thromboembolism (VTE), approximately 10%. We performed a systematic review to evaluate the efficacy and safety of prophylactic anticoagulation in patients with NS.MethodsStudies evaluating prophylactic anticoagulation in NS were identified by an electronic search of MEDLINE and EMBASE databases until December 2021. Weighted mean proportion and 95% confidence intervals (CIs) of thromboembolic and haemorrhagic events were calculated using a fixed‐effects and a random‐effects model. The differences in the outcomes among groups were estimated as pooled odds ratio (OR) and corresponding 95% CI. Statistical heterogeneity was evaluated using the I2 statistic.ResultsFive cohort studies, for a total of 414 adult patients, were included. Only two studies had a control group. The weighted mean incidence of pulmonary embolism (PE) and deep vein thrombosis in patients who received VTE prophylaxis was 1.8% (95% CI: 0.6–3.5%; I2: 4.4%) and 0.9% (95% CI: 0.2–2.2%; I2: 43.4%) respectively. The weighted mean incidence of major bleeding in patients who received VTE prophylaxis was 2.3% (95% CI: 1–4.2%; I2: 25.4%). Patients with NS that received VTE prophylaxis had a non‐significant reduced risk of PE (OR: 0.63 (95% CI: 0.03–14.8; I2: 64.4%)) and an increased risk of major bleeding (OR: 2.08 (95% CI: 0.41–10.45; I2: 0%)) compared to patients with NS that did not receive VTE prophylaxis.ConclusionsOur findings suggest that prophylactic anticoagulation in adult patients with primary NS may reduce the risk of VTE, even if it may be associated with a not negligible bleeding risk.